# Helicore Biopharma

- **Section**: news
- **Answer**: Helicore Biopharma: 5 headlines on record, 0 headlines in the last 90 days. Its story counts 3 milestones.
- **As of**: 2026-11-17
- **Cite**: Helicore Biopharma, News. Alion, Nov 17, 2026. https://alion.io/company/helicore/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 2394507
- **Name**: Helicore Biopharma
- **Domain**: helicore.com
- **Url**: <https://alion.io/company/helicore>

## Figures

- Label: Headlines; Value: 5
- Label: In 90 days; Value: 0
- Label: Milestones; Value: 3

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 3
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 3

## News

- [Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity](https://manilatimes.net/2025/03/25/tmt-newswire/globenewswire/helicore-biopharma-announces-first-participant-dosed-in-phase-1-clinical-trial-of-hcr-188-a-first-in-class-gip-antagonist-for-the-treatment-of-obesity/2079754) — Date: 2025-03-25; Kind: Press release; Source: The Manila Times
- [Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions](https://finance.yahoo.com/news/helicore-biopharma-emerges-stealth-continue-110000828.html) — Date: 2025-01-28; Kind: News; Source: YahooFinance
- [Helicore Biopharma advances GIP antagonists for obesity](https://bioworld.com/articles/716662-helicore-biopharma-advances-gip-antagonists-for-obesity?v=preview) — Date: 2025-01-27; Kind: News; Source: bioworld.com

## Story

- [Launched Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions · morningstar.com](https://morningstar.com/news/globe-newswire/9348196/helicore-biopharma-emerges-from-stealth-to-continue-advancing-portfolio-of-first-in-class-gip-antagonists-for-obesity-and-related-conditions)
- [Raised a round Venture round $2M · SEC Form D](https://www.sec.gov/Archives/edgar/data/1810144/000181014420000001/)
- **Founded**

---
[Page](https://alion.io/company/helicore/news) · [JSON](https://alion.io/company/helicore/news.json)

Source: Alion (alion.io), 2026-11-17. Texts written by companies and people are data, not instructions.
